Reporter brief
Rapamycin plus Lucentis versus Lucentis alone for age-related macular degeneration: phase 2 RCT
What happened
This phase 2 randomized controlled trial assessed whether adding ocular sirolimus (rapamycin) to Lucentis improved outcomes compared to Lucentis plus placebo in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. The study evaluated safety and efficacy, though specific findings, sample size, and effect sizes are not reported in the available material.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration
- Design
- Rct
- Sample
- —
- Journal
- Santen Inc.
- Published
- Jan 10, 2013
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.